Medicaid Rebates For Brands Could Rise $3.2Bn Over Next Decade Under New Law
Provision included in appropriations legislation directs manufacturers to calculate average prices for brands without including the cost of authorized generics, which will lead to higher rebates.
You may also be interested in...
Medicaid Rebate Ceiling Raised To 125% In Senate Legislation
Senate Finance Committee's drug pricing bill would also exclude authorized generics from calculation of average manufacturer prices and rebates and authorize installment-type payments for curative gene therapies.
The Budget Blindside: Did Pharma Fight The Wrong Battle?
The bigger 'Donut Hole' discount is a rare loss for pharma on Capitol Hill – one that may in part be because industry did too good a job fighting off a different drug pricing measure.
Keytruda, Opdivo May Be Only Part B Drugs Chosen For Medicare Negotiation In First Applicable Year
In general, more Part D drugs will be eligible than Part B drugs in the early years of the program because Part D drugs have higher levels of spending and so will dominate the list of candidates. A new report sizes up the drugs that would qualify for Medicare Price negotiation in 2026-2028.